Press Release | Coenzyme Q10 supplementation on metabolic profiles of patients with chronic kidney disease


Chronic Kidney disease (CKD) is highly associated with all-cause mortality, Diabetic Nephropathy (DN), cardiovascular events and hospitalization whether the patient has an existing risk or current cardiovascular disease or not. CKD can increase the chances of cardiovascular disease by two to fifty times and 50% mortality of patients with end stage renal disease (ESRD) on dialysis attributed to CVD and its complications. In this review, Co-enzyme Q10 (CoQ10) was tested as a potential treatment for CKD. The systemic review and meta-analysis of randomized control trials (RCTs) was conducted to evaluate the effects of CoQ10 supplementation on metabolic profiles of patients diagnosed with CKD.

CoQ10 is a potent lipophilic antioxidant that couple’s electron transport to oxidative phosphorylation in mitochondria. It is generally used as an alternative and complementary therapy for diseases with metabolic disorders. The supplementary protein has shown beneficial effects during the treatment of heart failure. It was found that the circulating concentration in patients with CKD had been decreased. This suggested that the CoQ10 antioxidant treatment would be an ideal solution for the disease. The results accumulated during meta-analysis proved that the CoQ10 supplementation significantly reduced total-cholesterol, malondialdehyde, and creatinine levels in patients diagnosed with CKD. It did not affect Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations. Read full press release to find out more at:



The article by Dr. Zatollah Asemi et al. is published in Current Pharmaceutical Design, Volume 24, Issue 31, 2018. To obtain the article, please visit:

Open Access Article – Control of Risk Factors for Cardiovascular Disease among Multinational Patient Population in the Arabian Gulf – Current Vascular Pharmacology

Journal: Current Vascular Pharmacology

Author(s): Ibrahim Al-Zakwani, Wael Al-Mahmeed, Mohamed Arafah, Ali T. Al-Hinai, Abdullah Shehab, Omer Al-Tamimi, Mahmoud Al-Awadhi,Shorook Al-Herz, Faisal Al-Anazi, Khalid Al-Nemer, Othman Metwally, Akram Al-Khadra, Mohammed Fakhry, Hossam Elghetany, Abdel R. Medani,Afzal H. Yusufali, Obaid Al-Jassim, Omar Al-Hallaq, Fahad O.A.S. Baslaib, Haitham Amin, Raul D. Santos, Khalid Al-Waili, Khamis Al-Hashmi,Khalid Al-Rasadi.


We evaluated the control of cardiovascular disease (CVD) risk factors among patients with atherosclerotic cardiovascular disease (ASCVD) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolaemia (CEPHEUS) in the Arabian Gulf. Of the 4398 enrolled patients, overall mean age was 57 ± 11 years, 60% were males, 13% were smokers, 76% had diabetes, 71% had metabolic syndrome and 78% had very high ASCVD risk status. The proportion of subjects with body mass index <25 kg/m2, HbA1c <7% (in diabetics), low-density lipoprotein cholesterol (LDL-C) <2.6 mmol/L (100 mg/dL) and <1.8 mmol/L (70 mg/dL) for high and very high ASCVD risk cohorts, respectively and controlled blood pressure (<140/90 mmHg) was 14, 26, 31% and 60%, respectively. Only 1.4% of the participants had all of their CVD risk factors controlled with significant differences among the countries (P < .001). CVD risk goal attainment rates were significantly lower in those with very high ASCVD risk compared with those with high ASCVD risk status (P < .001). Females were also, generally, less likely to attain goals when compared with males (P < .001).

Read more here:

%d bloggers like this: